Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|October 17, 2012
FDA approves treatment for cystinosis
The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA requires NAION warning across the GLP-1 receptor agonist class
2
Anti-VEGF switches for persistent fluid: A review of 3 clinical cases
3
City Therapeutics doses first participant in phase 1 trial of RNAi therapy CITY-RBP4 for Stargardt disease
4
Longer anti-VEGF intervals in AMD, BRVO, and DME: 3 clinical cases
5